ClinicalTrials.gg
Active, not recruitingNCT04868396Updated Oct 13, 2026

Patient-derived Glioma Stem Cell Organoids

An observational study in Glioblastoma, sponsored by Maastricht Radiation Oncology. Active, not recruiting at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Maastricht Radiation Oncology · Observational

How we know

Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Glioblastoma with a site in Netherlands — 24 open to participants now, 33 under way, 5 of them phase 3. Glioblastoma · Netherlands.

Planned enrollment
11th of 15
60 · median 325
Started
2021
with 5 others
Observational
15 of 92
8 open now
Primary completion
2027-01
later than 10 of 32 live
Registered
59th of 92
by date
Lead sponsor
7 of 92
Maastricht Radiation Oncology

Among the 92 studies in Glioblastoma with a site in Netherlands, this one is the 11th largest by planned enrollment of the 15 observational ones that give a count, is one of 6 that started in 2021, is one of 15 observational ones, reaches primary completion later than 10 of the 32 other live ones, and was the 59th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

24 of the 92 studies in Glioblastoma with a site in Netherlands are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Glioblastoma with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale: Glioblastoma (GM) is the most frequent incurable adult brain tumor with median survival of 15 months after diagnosis, despite extensive treatment with surgery, radiation therapy and chemotherapy. Tumor recurrence is inevitable after which life prolonging therapies are no longer available. The development of new treatments for GM is being hampered by inter-and intratumoral heterogeneity of tumors and their microenvironment, which currently cannot be predicted accurately with current diagnostics.

Objective: To establish primary patient derived organoid cultures from GM to study mechanisms that contribute to aggressive tumor growth and treatment resistance in primary and recurrent GM.

Study design: Preclinical study, using patient derived glioblastoma tissue. Study population: Patients 18 years or older, with newly diagnosed glioblastoma.

Main study parameters/endpoints: Intra-and inter organoid genetic and epigenetic heterogeneity that is representative for GM. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Minimal burden, since the biopsies are part of a regular neurosurgical procedure (debulking); which intends to eradicate the macroscopical tumorload in order to optimize survival benefit. The tissue (biopsy) that will be used for this trial is part of the tumor tissue that is resected during the standard debulking.

Benefit: no benefit for the patient.

Read the detailed description

Patients with glioblastoma (GM) have a median overall survival of approximately 15 months.Standard therapy for GM encompasses maximum surgical resection followed by radiation and chemotherapy using temozolomide (TMZ) (1). Regardless of initial tumor response, tumor recurrence is inevitable, after which survival drops to less than 6 months. GM tailored approaches targeting oncogenes that might drive the growth of the bulk of primary tumors, have been unsuccessful so far in clinical trials(2), creating a large unmet need warranting new approaches to overcome intrinsic and acquired resistance to current treatment schedules. The objective of this research is to establish primary patient derived organoid cultures from GM to study mechanisms that contribute to aggressive tumor growth and treatment resistance in primary and recurrent GM.

  1. Inter-and intratumoral heterogeneity in glioblastoma. Tumor tailored approaches for GM are being hampered by inter-and intratumoral heterogeneity of both microenvironment and genomic alterations in GM cells. It has been shown that tumors are composed of multiple clones harboring distinct genetic alterations (3-7). The clonal evolution model posits that tumor formation is initiated in a cell of origin and is followed by the subsequent accumulation of multiple genetic and epigenetic alterations, leading to tumor cell survival and growth advantage (8). Divergent genetic alterations in early transformed cells give rise to a variety of clones under the selective pressure of the tumor microenvironment (3-7). An important microenvironmental stressor is intratumoral hypoxia, which is frequent in GM and a negative prognostic and predictive factor associated with reduced survival (9,10).

    Emerging evidence implicates a subpopulation of tumor cells with characteristics of normal stem cells so-called glioma stem cells (GSC) in intrinsic and acquired treatment resistance. GSC are endowed with specific properties including high tumor initiating ability, unlimited self-renewal potential and capacity for multipotent differentiation, generating a diverse progeny(11). GSC are marked by common stem cell markers including CD133+, SOX2, Olig1, and have been shown to reside in the perivascular region as well as in hypoxic areas. GSC are expanded under hypoxia12depend on glycolysis (13,14).

    Combined with their low proliferation, increased DNA repair, high anti-oxidant activity and among others, make GCS more resistant to conventional treatments (radiation and temozolomide) then non-GSC (15,16) {Jamal, 2012 #52}.

    This implies that GSCs form an important driver of GM recurrence after chemoradiation. There are currently no effective treatments to eliminate glioma stem cells. Blocking hypoxia signalling in tumors (inhibiting self-renewal and survival of GSC cells)(12,17) and blocking the NOTCH stem cell pathway (rendering GSCs sensitive to radiation(18) and TMZ(19-21)), seem to promising but drugs interfering with these pathways have not passed beyond early phase clinical trials yet(22).

    Current standard of care of newly diagnosed glioblastoma is multimodal and consists of surgery, radiation therapy and TMZ, an alkylating agent modifying purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). The addition of TMZ to radiotherapy has increased the overall survival of GM patients significantly, but only up to 14.6 months(1). Intratumoral hypoxia has been shown to decrease therapeutic efficacy of RT and chemotherapy(23). Hypoxic GM cells are genetically unstable and show increased MGMT expression and thereby resistance to alkylating TMZ chemotherapy(24).

    In non-GSCs, MGMT promoter methylation is a predictive marker for response to TMZ treatment(25,26). However the interpretation of the MGMT methylation assay is complex, since the extent of MGMT promoter methylation in GM is heterogeneous and the level of heterogeneity is underestimated, since only GM biopsies or fragmented GM tissue is being analysed(27,28). Importantly, MGMT is also expressed in the normal brain endothelial cells and in immune cells including tumor infiltrating cells(29). Thus depending on the extent of normal tissue contamination in GM biopsies the level MGMT methylation may also differ.

    Since intra-tumoral heterogeneity in MGMT expression cannot be objectivated using currently available diagnostics and since undertreatment of patients should be prevented at all times, at present most patients diagnosed with ´de novo´ GM, receive TMZ; although there seems to be little benefit of TMZ in GMs with MGMT unmethylated glioma cells.

    Designing new treatment protocols for newly diagnosed glioblastoma is quite complex, since diagnostic tools, predicting inter-and intra-GM heterogeneity of MGMT promoter methylation status (or level of MGMT expression), are lacking. Additionally, the level of MGMT expression, needed for significant TMZ response and improvement of clinical outcome, is not known. Thus since most GMs are defined by both MGMT methylated and MGMT unmethylated tumor clones, combining TMZ with drugs that target non-methylated glioma cells/glioma stem cells and/or microenvironment might be necessary.

  2. Glioblastoma recurrence Even if a macroscopically complete resection of a GM can be achieved, tumor cells remain at the resection site. It has been shown that GM cells have a high capacity for dissemination. Invading tumor cells escape at the periphery of the tumor mass and diffusely infiltrate the normal brain parenchyma. Deeply infiltrated tumor cells are more likely to escape surgery and what is not known is whether infiltration is a property of a more resilient cell population that initiates and drives tumor recurrence. Even after postoperative chemotherapy and radiation outside of the field of surgery to reduce infiltrative tumor cells, almost all GM recur, mostly around the resection cavity. If a gross total resection cannot be performed; primary radiation therapy and chemotherapy are also able to reduce clonal diversity, but are thus insufficient to prevent recurrence.

This implies that tumor cells resistant to multiple therapies persist in the brain parenchyma around the tumor cavity after gross total resection or in the remaining tumor after chemoradiation which are responsible for tumor repopulation, making them a critical target to overcome tumor recurrence. Genomic analysis of GM has shown that dominant clones in recurrent tumors are composed of clones representative of the primary tumor as well as new clones with little resemblance to the original tumor(3,30,31,32,33). Consequently targets identified based on the analysis of the primary tumor may not be informative to identify the best molecular targets to prevent recurrence(5).

After failure of first line GM treatment (radiation, TMZ), recurrence seems to be accompanied with a phenotypic shift of GSCs to the mesenchymal (MES) subtype (loss of CD133; gain of BMI1, SOX2 and CD44)(34-38). Such cells are more aggressive, invasive and angiogenic than primary tumor derived GSCs, mostly the proneural (PN) subtype (CD133+, CD15+)(39-41). MES GSC also show a higher expression of the inflammasome genes, such as IL6, IL8, IL1B1C and CXCL2, reinforcing the notion that interplay with the microenvironment and plays an important role in recurrence and progression(42,43). GM specific clinical trials are being developed, using immune modulators. It has been shown that MSH (mutS homologue) mutations correlate with TMZ resistance, as they are neither found in pre-treatment GM nor radiotherapy post-treatment GM, but were detected in approximately half of recurrent GM patients treated with TMZ and radiotherapy. This strongly indicates that MSH6 alterations are associated with resistance to alkylating agent therapy. Thus GM patients who initially respond to TMZ may acquire MMR defective hypermutator phenotype(44-46). It is well established that an intact mismatch repair and base excision repair (BER) contribute to effective TMZ cytotoxicity. Pharmacological inhibition of BER using PARP inhibitors either alone or in combination with TMZ has shown promise in clinical trials. However, acquired resistance to PARP inhibitors is observed through up-regulation of base excision repair and homologous recombination repair to compensate for diminished BER (47,48).

In conclusion, understanding the therapy induced genetic and epigenetic alterations of the remaining tumor cells and GSCs and also the impact of standard of care to the microenvironment /niche, in which recurrence occurs, will guide the development of new treatments.

In this project we will use patient derived glioma stem cell organoids(49), mimicking de novo GM and its intratumoral heterogeneity. Also these patient-derived organoids (PDO) organoids will be used to study acquired temozolomide resistance and thus can be used for identifying novel targeted agents.

Tumor cell heterogeneity in MGMT expression and its relevance for TMZ response will also be addressed using these organoids, using single cell proteomics and IHC for MGMT, GSC markers and exome sequencing (for common driver mutations) to identify those populations that clonally expand under TMZ (RT) selection and those that disappear.

Another interesting feature we will explore using PDO is the possibility to analyze the supernatants for circulating tumor DNA (ctDNA) or exosomes (secreted vesicles which contain RNA, small non-coding RNA, proteins as well as DNA) before during after acquired TMZ resistance which might lead to the identification of pharmacological response and predictive biomarkers. Such biomarkers 'liquid biopsy' may become useful to measure treatment response in blood or lumbar fluid of GM patients and enable dose-modification (escalation or deintensification or termination).

The development of the PDOs (costs of materials) will be funded (607061 PI M. Vooijs, MAASTRO and KWF grant Alpe D'Huzes PI M.Vooijs, MAASTRO. There are no additional costs associated with obtaining the tumor tissue.

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • Stem cells
  • Organoids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All these patients regardless of sex and ethnicity will be asked to co-operate in this study.

The patients will be consecutively included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MRI imaging suggestive for glioblastoma
  • > 18 years of age

Exclusion criteria

Exclusion Criteria:

  • index \< 70
  • Clotting disorders
  • Neurosurgical for gross total resection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Glioblastoma patients

    Glioblastoma patients selected to undergo surgical removal of a glioblastoma (based on MRI image).

    Procedure: Tumor biopsy

Interventions

  • ProcedureTumor biopsy

    Tumor material will be derived from 'left-over' tumor tissue that is not needed for standardised diagnostics (immune histochemistry and molecular testing).

06

What researchers measure

Primary outcomes

  1. Organoid cultures

    Primary derived organoid cultures from GM

    Time frame: Baselline

  2. Long term culturing and biobanking conditions for GM organoids

    Determine the frequency of primary, secondary and tertiary organoid formation, size distribution of the organoids, the rate of proliferation and cell death will be calculated.

    Time frame: Baseline

  3. Intra-organoid heterogeneity reflects intra-tumoral genetic and epigenetic heterogeneity

    To assess whether intra-organoid heterogeneity reflects intra-tumoral genetic and epigenetic heterogeneity; with initial focus on MGMT promoter methylation status

    Time frame: Baseline

  4. GM organoid model

    GM organoid model that reflects primary and secondary temozolomide resistance

    Time frame: Baseline

Secondary outcomes

  1. Define oncogenic drivers

    Define oncogenic drivers in TMZ resistant GM cells.

    Time frame: Baseline

  2. Organoid platform

    Set up organoid platform (MGMT methylated vs non-methylated) for drug screening.

    Time frame: Baseline

  3. ctDNA

    Analyse ctDNA, secreted by organoids in medium/supernatans and corresponding patient derived plasma.

    Time frame: Baseline

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2021 (actual). Primary completion is estimated for Jan 2027, 68 months after the start.

Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 68 months is above that.

Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2025 → Jan 2027 and completion Sep 2025 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2021
First posted
Apr 30, 2021
StartActual
Apr 10, 2021
Primary completionEst.
Jan 1, 2027was Sep 2025
CompletionEst.
Jan 1, 2027was Sep 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2025→Jan 1, 2027
Oct 13, 2026
Study completion
Sep 1, 2025→Jan 1, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Sep 1, 2025→Jan 1, 2027
    Study completion Sep 1, 2025→Jan 1, 2027
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04868396
Responsible party
Sponsor
First posted
Apr 30, 2021
Start date
Apr 10, 2021
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Marc Vooijs, Prof. Dr.
principal investigator · Maastro Radiaton Oncology
A. Hoeben, Dr.
principal investigator · Maastricht UMC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion